These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27048801)

  • 1. The Importance of First Impressions: Early Events in Mycobacterium tuberculosis Infection Influence Outcome.
    Cadena AM; Flynn JL; Fortune SM
    mBio; 2016 Apr; 7(2):e00342-16. PubMed ID: 27048801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking Transmission with Vaccines: The Case of Tuberculosis.
    Gonzalo-Asensio J; Aguilo N; Marinova D; Martin C
    Microbiol Spectr; 2017 Jul; 5(4):. PubMed ID: 28710848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human biomarkers: can they help us to develop a new tuberculosis vaccine?
    Fletcher HA; Dockrell HM
    Future Microbiol; 2016 Jun; 11():781-7. PubMed ID: 27203133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design.
    Karbalaei Zadeh Babaki M; Soleimanpour S; Rezaee SA
    Microb Pathog; 2017 Nov; 112():20-29. PubMed ID: 28942172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: in vitro studies in humans.
    Mustafa AS
    Expert Rev Vaccines; 2009 Oct; 8(10):1309-12. PubMed ID: 19803751
    [No Abstract]   [Full Text] [Related]  

  • 7. Tuberculosis vaccine research: the impact of immunology.
    Barker LF; Brennan MJ; Rosenstein PK; Sadoff JC
    Curr Opin Immunol; 2009 Jun; 21(3):331-8. PubMed ID: 19505813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.
    Baldwin SL; Reese VA; Huang PW; Beebe EA; Podell BK; Reed SG; Coler RN
    Clin Vaccine Immunol; 2016 Feb; 23(2):137-47. PubMed ID: 26656121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis.
    Dhanda SK; Vir P; Singla D; Gupta S; Kumar S; Raghava GP
    PLoS One; 2016; 11(4):e0153771. PubMed ID: 27096425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rational vaccine pipeline for tuberculosis.
    Brennan MJ; Stone MR; Evans T
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1566-73. PubMed ID: 23131253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
    Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
    Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J; Doherty TM
    APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice.
    Mustafa AD; Kalyanasundram J; Sabidi S; Song AA; Abdullah M; Abdul Rahim R; Yusoff K
    BMC Biotechnol; 2018 Oct; 18(1):63. PubMed ID: 30309359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique model of dormant infection for tuberculosis vaccine development.
    Kashino SS; Ovendale P; Izzo A; Campos-Neto A
    Clin Vaccine Immunol; 2006 Sep; 13(9):1014-21. PubMed ID: 16960113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.
    Sambandamurthy VK; Derrick SC; Hsu T; Chen B; Larsen MH; Jalapathy KV; Chen M; Kim J; Porcelli SA; Chan J; Morris SL; Jacobs WR
    Vaccine; 2006 Sep; 24(37-39):6309-20. PubMed ID: 16860907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential proteomics approach to identify putative protective antigens of Mycobacterium tuberculosis presented during early stages of macrophage infection and their evaluation as DNA vaccines.
    Sharma S; Rajmani RS; Kumar A; Bhaskar A; Singh A; Manivel V; Tyagi AK; Rao KV
    Indian J Exp Biol; 2015 Jul; 53(7):429-39. PubMed ID: 26245027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.